These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30229374)

  • 1. A QALY loss is a QALY loss is a QALY loss: a note on independence of loss aversion from health states.
    Lipman SA; Brouwer WBF; Attema AE
    Eur J Health Econ; 2019 Apr; 20(3):419-426. PubMed ID: 30229374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospect theory in the health domain: a quantitative assessment.
    Attema AE; Brouwer WB; I'Haridon O
    J Health Econ; 2013 Dec; 32(6):1057-65. PubMed ID: 24103499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QALYs without bias? Nonparametric correction of time trade-off and standard gamble weights based on prospect theory.
    Lipman SA; Brouwer WBF; Attema AE
    Health Econ; 2019 Jul; 28(7):843-854. PubMed ID: 31237093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Corrective Approach: Policy Implications of Recent Developments in QALY Measurement Based on Prospect Theory.
    Lipman SA; Brouwer WBF; Attema AE
    Value Health; 2019 Jul; 22(7):816-821. PubMed ID: 31277829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia.
    Palmer AJ; Campbell JA; de Graaff B; Devlin N; Ahmad H; Clarke PM; Chen M; Si L
    Health Econ; 2021 Aug; 30(8):1950-1977. PubMed ID: 34018630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating sign-dependent societal preferences for quality of life.
    Attema AE; Brouwer WB; l'Haridon O; Pinto JL
    J Health Econ; 2015 Sep; 43():229-43. PubMed ID: 26263893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporating sign-dependence in health-related social welfare functions.
    Attema AE
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):223-8. PubMed ID: 25543906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [QALYS or not QALYS: that is the question?].
    Moatti JP; Auquier P; Le Coroller AG; Macquart-Moulin G
    Rev Epidemiol Sante Publique; 1995 Dec; 43(6):573-83. PubMed ID: 8552855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A test of independence of discounting from quality of life.
    Attema AE; Brouwer WB
    J Health Econ; 2012 Jan; 31(1):22-34. PubMed ID: 22277284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The validity of QALYs: an experimental test of constant proportional tradeoff and utility independence.
    Bleichrodt H; Johannesson M
    Med Decis Making; 1997; 17(1):21-32. PubMed ID: 8994148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monetised estimated quality-adjusted life year (QALY) losses for non-fatal injuries.
    Miller GF; Florence C; Barnett SB; Peterson C; Lawrence BA; Miller TR
    Inj Prev; 2022 Oct; 28(5):405-409. PubMed ID: 35296543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivariate risk preferences in the quality-adjusted life year model.
    Attema AE; Frasch JJ; L'Haridon O
    Health Econ; 2022 Feb; 31(2):382-398. PubMed ID: 34796588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A utility-theoretic model for QALYs and willingness to pay.
    Klose T
    Health Econ; 2003 Jan; 12(1):17-31. PubMed ID: 12483758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010.
    Wisløff T; Hagen G; Hamidi V; Movik E; Klemp M; Olsen JA
    Pharmacoeconomics; 2014 Apr; 32(4):367-75. PubMed ID: 24477679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
    Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
    Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A test of the QALY model when health varies over time.
    Spencer A
    Soc Sci Med; 2003 Nov; 57(9):1697-706. PubMed ID: 12948578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.